|Day Low/High||4.10 / 4.20|
|52 Wk Low/High||0.25 / 1.94|
TheStreet's biotech columnist offers his own report card on biotech stocks.
A look back at the year's worth of Adam Feuerstein's biotech tweets.
Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.
Trial demonstrates statistically significant improvement in spleen volume reduction (SVR) with pacritinib compared to best available therapy (BAT), including ruxolitinib
-72 week follow up of patients with myelofibrosis, including patients with baseline thrombocytopenia, show pacritinib treatment led to durable reductions in spleen volume and symptom burden-
Stocks with insider trader activity include LPNT, PATK and CTIC
- Four abstracts selected to be presented on pacritinib highlighting additional safety and long-term follow up data from Phase 3 PERSIST-1 trial -
Additional pacritinib data also presented at AACR
- Five abstracts selected to be presented on pacritinib -
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of CTI BioPharma Corp.
Lundin Law PC announces a class action lawsuit has been filed against CTI BioPharma Corp.
Law Offices of Howard G. Smith reminds investors of the upcoming April 11, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased CTI BioPharma Corp.
Stocks with insider trader activity include SPTN, FL and CTIC
Stocks with insider trader activity include ATRS, CMT and CTIC